期刊文献+

Oncogenic Osteomalacia Associated with Phosphaturic Mesenchymal Tumor of the Knee: Case Presentation and Review of the Literature

Oncogenic Osteomalacia Associated with Phosphaturic Mesenchymal Tumor of the Knee: Case Presentation and Review of the Literature
下载PDF
导出
摘要 Oncogenic osteomalacia (OOM) is an uncommon metabolic and bone disease caused by fibroblast growth factor 23 (FGF23), a phosphaturic factor produced by phosphaturic mesenchymal tumors (mixed connective tissue variant, PMTMCTV) characterized by phosphate leakage from kidneys and subsequent hypophosphatemia. In this paper, we present the case of a patient, 42-year-old woman affected by left side limp and pain involving lumbar spine, pelvis and hip joints, referred to the Rheumatology Department of our Hospital for the treatment of a suspected sero-negative spondilo-arthritis. During hospitalization patient began an immuno-suppressive therapy with TNF-alpha inhibitors associated with Pamidornate, Indometacin, Esomeprazole and vitamin D3. Nevertheless pain did not decrease and a new examination found a worst hypophosphatemia (1 mg/dl) with normal Ca and PTH’s plasma values. During the same check-up a painful bulge on the anterior part of the right knee was observed and the Magnetic Resonance Imaging scan revealed an ovular solid lesion in the soft tissue closed to the upper part of the patella. Histological analysis identified the lesion as a PMTMCTV. After surgical removal patient got complete recovery. We will discuss about diagnostic evaluation, differential diagnosis and treatment. Oncogenic osteomalacia (OOM) is an uncommon metabolic and bone disease caused by fibroblast growth factor 23 (FGF23), a phosphaturic factor produced by phosphaturic mesenchymal tumors (mixed connective tissue variant, PMTMCTV) characterized by phosphate leakage from kidneys and subsequent hypophosphatemia. In this paper, we present the case of a patient, 42-year-old woman affected by left side limp and pain involving lumbar spine, pelvis and hip joints, referred to the Rheumatology Department of our Hospital for the treatment of a suspected sero-negative spondilo-arthritis. During hospitalization patient began an immuno-suppressive therapy with TNF-alpha inhibitors associated with Pamidornate, Indometacin, Esomeprazole and vitamin D3. Nevertheless pain did not decrease and a new examination found a worst hypophosphatemia (1 mg/dl) with normal Ca and PTH’s plasma values. During the same check-up a painful bulge on the anterior part of the right knee was observed and the Magnetic Resonance Imaging scan revealed an ovular solid lesion in the soft tissue closed to the upper part of the patella. Histological analysis identified the lesion as a PMTMCTV. After surgical removal patient got complete recovery. We will discuss about diagnostic evaluation, differential diagnosis and treatment.
出处 《International Journal of Clinical Medicine》 2013年第7期24-27,共4页 临床医学国际期刊(英文)
关键词 Four PARANEOPLASTIC Syndrome Oncogenic OSTEOMALACIA Phosphaturia Phosphaturic Mesenchymal Tumors KNEE Localization HYPOPHOSPHATEMIA FIBROBLAST Growth Factor 23 (FGF23) Sero-Negative Spondilo-Arthritis Complete Recovery Kidney Tubular REABSORPTION Four Paraneoplastic Syndrome Oncogenic Osteomalacia Phosphaturia Phosphaturic Mesenchymal Tumors Knee Localization Hypophosphatemia Fibroblast Growth Factor 23 (FGF23) Sero-Negative Spondilo-Arthritis Complete Recovery Kidney Tubular Reabsorption
  • 相关文献

参考文献1

二级参考文献37

  • 1Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalaciaassociated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature [J]. Am J Surg Pathol, 2004,28( 1 ): 1 - 30.
  • 2Econs M J, Drezner MK. Tumor-induced osteomalaciaunveiling a new hormone [J]. N Engl J Med, 1994,330(23): 1679-1681.
  • 3Ramon I, Kleynen P, Body J J, et al. Fibroblast growth factor 23 and its role in phosphate homeostasis [J]. Eur J Endocrinol, 2009,162(1):1-10.
  • 4Yoshioka K, Nagata R, Ueda M, et al. Phosphaturic mesenchymal tumor with symptoms related to osteomalacia that appeared one year after tumorectomy [J]. Intern Med, 2006,45(20): 1157-1160.
  • 5Nasu T, Kurisu S, Matsuno S, et al. Tumor-induced hypophosphatemic osteomalacia diagnosed by the combinatory procedures of magnetic resonance imaging and venous sampling for FGF23 [J]. Intern Med, 2008,47(10):957-961.
  • 6Takeuchi Y, Suzuki H, Ogura S, et al. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia [J]. J Clin Endocrinol Metab, 2004,89( 8):3979 - 3982.
  • 7Bahrami A, Weiss SW, Montgomery E, et al. RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia [J]. Am J Surg Pathol, 2009,33(9): 1348-1354.
  • 8Liu S, Quarles LD. How fibroblast growth factor 23 works [J]. J Am Soc Nephrol, 2007,18(6):1637-1647.
  • 9Seijas R, Ares O, Sierra J, et al. Oncogenic osteomalacia: two case reports with surprisingly different outcomes [J]. Arch Orthop Trauma Surg, 2009,129(4):533-539.
  • 10Uramoto N, Furukawa M, Yoshizaki T. Malignant phosphaturic mesenchymal tumor, mixed connective tissue variant of the tongue [J]. Auris Nasus Larynx, 2009,36(1):104-105.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部